Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Back to Jobs

OTO-313 Phase 2 trial in tinnitus fully enrolled ahead of schedule with top-line results expected in mid-2022; initiating safety evaluation of higher and bilateral dosing OTO-413 Phase 2a cohort in hearing loss fully enrolled with top-line results expected early in second quarter of 2022;

Apply Now